Should You Buy Supernus Pharmaceuticals, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Supernus Pharmaceuticals, Inc. (SUPN) occupies a solid middle-ground position with a Quality of Company score of 7.2/10. At the current market price of $41.28, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 1 of 7 CirclFi valuation models project upside for Supernus Pharmaceuticals, Inc. (SUPN) at $41.28 — the model consensus leans bearish, with a Quality Score of 7.2/10 and Value-Trap risk of 19/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Supernus Pharmaceuticals, Inc. (SUPN) in 2026?
What Is the Bull Case vs the Bear Case for Supernus Pharmaceuticals, Inc. (SUPN)?
| Bull case — $93.48 target (+126.5%) | Bear case — $9.77 target (-76.3%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Supernus Pharmaceuticals, Inc.'s quality score of 7.2/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. | According to the CirclFi Deep Alpha Valuation Engine, the Sentiment SOTP model sees the stock as overvalued with a fair value of $9.77 (-76.3%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $93.48 (+126.5%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +202.8% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry tailwind: licensing and M&A optionality could provide meaningful support for Supernus Pharmaceuticals, Inc.'s revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. | Industry headwind: generic/biosimilar competition represents a meaningful risk for Supernus Pharmaceuticals, Inc. and its Drug Manufacturers - Specialty & Generic peers. |
How Does SUPN Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: TRLV · ELAN · CRON · INDV · PCRX · ETON · AYTU · HYEX · BGM · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like SUPN on Quality?
Closest companies to SUPN’s Quality of Company score of 7.2/10, across all industries.
Which Drug Manufacturers - Specialty & Generic Screens Does SUPN Appear In?
So Is Supernus Pharmaceuticals, Inc. (SUPN) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Supernus Pharmaceuticals, Inc. at $41.28. 6/7 models flag overvaluation, median fair value sits at $24.02 (-41.8%), and the risk-reward profile appears unfavorable. Quality at 7.2/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Supernus Pharmaceuticals, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About SUPN Stock?
Should I buy SUPN stock right now?
Based on CirclFi's multi-model analysis, 1 of 7 models see upside for SUPN at $41.28. The models are divided, which means the investment case depends heavily on your assumptions about Supernus Pharmaceuticals, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Supernus Pharmaceuticals, Inc.?
Key risks include: limited model coverage (7/13 active), reducing analytical confidence; wide model disagreement (857% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does SUPN compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, SUPN holds a Quality Score of 7.2/10. Comparable companies include TRLV (QOC 7.3), ELAN (QOC 7.2), CRON (QOC 7.4). The relative ranking helps investors identify whether SUPN offers better fundamental quality than alternatives in the same sector.
Is SUPN a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. SUPN's Quality Score of 7.2/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy SUPN at?
CirclFi does not provide target buy prices or price alerts. However, our 7 active models produce fair value estimates ranging from $9.77 to $93.48. At $41.28, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for SUPN.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad